Summary:
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,
MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND
TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE
PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE
CURRENT EPISODE IS MANIC OR DEPRESSIVE, WITH OR WITHOUT MIXED
FEATURES
Qualified Participants Must:
• Male or female 18 to 65 years of age
Qualified Participants May Receive:
Compensaton for time and travel